Endothelial dysfunction is a forerunner in the development of atherosclerosis, cardiovascular (CV) and renal disease [1]. A marker of endothelial dysfunction is an increase in urinary albumin excretion (UAE), known as albuminuria [2,3]. This condition is frequent in diabetic (DM) patients and has also been used to stratify CV and renal risk in patients with hypertension (HTN) and/or chronic kidney disease (CKD) [4,5]. Despite UAE being generated in the kidney, its value as a CV risk marker has been demonstrated in post-hoc analysis of clinical trials and prospective studies [6–12].
